As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Guizhou Yibai Pharmaceutical has two lines of business: manufacturing drugs and operating hospitals. The company manufactures traditional Chinese medicine, chemical-synthetic drugs, and biomedicines. It...
Quantum Hi-Tech (China) Biological primarily manufactures prebiotic products, which regulates and helps with digestion. The company imports lactose from the United States as an input for its products....
Top Choice Medical Investment focuses on oral health services and has expanded into in vitro fertilization in recent years. The company operates 22 dental clinics and one fertility center in Kunming, Yunnan...
Shanghai Shenqi Pharmaceutical manufactures over 200 types of products, including cancer treatment drugs, influenza vaccines, cardiovascular disease treatments, and others. It is primarily focused on the...
Furen Pharmaceutical Group manufactures flu vaccines, painkillers, digestive drugs, and other products. It is currently primarily focused on the domestic China market but signed an agreement with Indian...